Conservative treatment of prosthetic valve endocarditis due to Mycobacterium fortuitum.
Described here is the case of a patient with infective endocarditis in a prosthetic valve due to a Mycobacterium fortuitum-group organism. The patient was treated medically and had a favorable clinical response. This is only the second report of survival after Mycobacterium fortuitum-group endocarditis, and the first of survival without surgical intervention. The duration of treatment is not well defined for this patient, but life-long suppressive therapy will likely be required.
Kunin
M
M
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Salamon
F
F
Weinberger
M
M
Genkin
I
I
Sagie
A
A
Tur-Kaspa
R
R
D000368:Aged; D000583:Amikacin / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D002939:Ciprofloxacin / Q000627:therapeutic use; D004697:Endocarditis, Bacterial / Q000188:drug therapy* / Q000382:microbiology*; D006350:Heart Valve Prosthesis / Q000382:microbiology*; D006801:Humans; D008297:Male; D000077731:Meropenem; D009164:Mycobacterium Infections / Q000188:drug therapy* / Q000382:microbiology; D019907:Mycobacterium fortuitum / Q000302:isolation & purification*; D016459:Prosthesis-Related Infections / Q000188:drug therapy* / Q000382:microbiology*; D013845:Thienamycins / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D013845:Thienamycins; D002939:Ciprofloxacin; D000583:Amikacin; D000077731:Meropenem